JP2020505056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505056A5 JP2020505056A5 JP2019545850A JP2019545850A JP2020505056A5 JP 2020505056 A5 JP2020505056 A5 JP 2020505056A5 JP 2019545850 A JP2019545850 A JP 2019545850A JP 2019545850 A JP2019545850 A JP 2019545850A JP 2020505056 A5 JP2020505056 A5 JP 2020505056A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- nanobody
- nanobody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 150000001413 amino acids Chemical class 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102000013498 tau Proteins Human genes 0.000 claims 4
- 108010026424 tau Proteins Proteins 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1660450 | 2016-10-27 | ||
| FR1660450A FR3058143B1 (fr) | 2016-10-27 | 2016-10-27 | Nanocorps anti-tau |
| PCT/EP2017/077691 WO2018078140A1 (fr) | 2016-10-27 | 2017-10-27 | Nanocorps anti-tau |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505056A JP2020505056A (ja) | 2020-02-20 |
| JP2020505056A5 true JP2020505056A5 (https=) | 2020-12-03 |
| JP7197494B2 JP7197494B2 (ja) | 2022-12-27 |
Family
ID=58314353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545850A Active JP7197494B2 (ja) | 2016-10-27 | 2017-10-27 | 抗Ｔａｕナノボディ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10590191B2 (https=) |
| EP (1) | EP3532495A1 (https=) |
| JP (1) | JP7197494B2 (https=) |
| CN (1) | CN110225926B (https=) |
| CA (1) | CA3041066A1 (https=) |
| FR (1) | FR3058143B1 (https=) |
| WO (1) | WO2018078140A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| CN112649615A (zh) * | 2020-12-21 | 2021-04-13 | 大连理工大学 | 一种检测不同大小的可溶性Aβ寡聚体的方法及应用 |
| FR3134390B1 (fr) | 2022-04-11 | 2025-10-24 | Univ Grenoble Alpes | Peptide utile pour le transport de molecules au travers de barrieres cellulaires |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| HU222398B1 (hu) | 1994-09-12 | 2003-06-28 | Schering Aktiengesellschaft | Eljárás pallidipin, egy módosított, kollagénindukált vérlemezke-aggregációt gátló vegyület előállítására |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU2010286501B2 (en) * | 2009-08-28 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Antibodies that bind Tau oligomers |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| EP2906596B1 (en) | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| BR112015030356A2 (pt) * | 2013-06-10 | 2017-12-05 | Ipierian Inc | métodos de tratamento de uma taupatia |
| EP2899208A1 (en) * | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
-
2016
- 2016-10-27 FR FR1660450A patent/FR3058143B1/fr active Active
-
2017
- 2017-10-27 CA CA3041066A patent/CA3041066A1/fr active Pending
- 2017-10-27 WO PCT/EP2017/077691 patent/WO2018078140A1/fr not_active Ceased
- 2017-10-27 US US16/345,279 patent/US10590191B2/en active Active
- 2017-10-27 EP EP17798139.6A patent/EP3532495A1/fr active Pending
- 2017-10-27 JP JP2019545850A patent/JP7197494B2/ja active Active
- 2017-10-27 CN CN201780080870.6A patent/CN110225926B/zh active Active